Abstract
Background Understanding whether apathy in older adults is related to incident dementia and mortality could help identify at-risk individuals, and inform public health efforts. This study aimed to investigate associations between apathy and these outcomes over long-term follow-up, and their independence from the overlapping symptoms of depression and fatigue.
Methods In an Australian population-based cohort of 1,030 community-dwelling older adults aged 70-90, without dementia at baseline, apathy was assessed using the self-report Geriatric Depression Scale-3A subscale. Incident dementia was established via consensus diagnosis over 12 year follow-up, and mortality by record linkage over 18 years. We calculated hazard ratios (HRs) using Cox proportional hazards analyses. We repeated analyses adjusting for depression, fatigue and covariates, accounting for competing risk of mortality, and excluding short-term cases.
Findings Unadjusted primary analyses showed the presence of self-reported apathy was associated with higher risk of dementia (HR 1.45, 95% confidence interval (CI) 1.05–2.00) and mortality (HR 1.76, 95% CI 1.43–2.16). Participants with apathy developed dementia a year earlier, and died three years earlier. These findings remained significant when adjusting for depression. The association with dementia was no longer significant when adjusting for fatigue or covariates, nor when taking mortality into account or excluding those cases where dementia developed in the shorter term.
Interpretation The presence of apathy may represent an important risk indicator for dementia and mortality in older adults without dementia, independent of depression. Its association with dementia may reflect reverse causality. Future studies are needed to better understand the causal relationships that may underpin this observed association in the short and long-term, and the utility of apathy for screening in public health settings.
Funding Dementia Australia Research Foundation, Centre for Healthy Brain Ageing.
Competing Interest Statement
H.B. is or has been an advisory board member or consultant to Biogen, Eisai, Eli Lilly, Medicines Australia, Roche, and Skin2Neuron. P.S.S. was a member of the Expert Advisory Committees for Biogen and Roche Australia in 2020-22, unrelated to the current work. He is supported by an NHMRC Investigator Grant. J.R. has received honorarium from Merck Sharp & Dohme (MSD) for giving educational talks to health professionals. All other authors declare they have no competing interests.
Funding Statement
This doctoral research was supported by co-funding from Dementia Australia Research Foundation-Dementia Collaborative Research Centres Half-Funded PhD Scholarship and the Centre for Healthy Brain Ageing (CHeBA), and top-up scholarships from CHeBA Josh Woolfson Memorial Scholarship and Kwan Fung and Yuet Ying Fung Healthy Brain Ageing Research Award Fund and Brain Sciences UNSW Collaborative PhD Grant-In-Aid. The Sydney Memory and Ageing Study has been funded by three National Health & Medical Research Council (NHMRC) Program Grants (ID No. ID350833, ID568969, and APP1093083). DNA samples were extracted by Genetic Repositories Australia, an Enabling Facility, which was supported by an NHMRC Grant (ID No. 401184). Blood samples were collected by South-Eastern Area Laboratory Service (SEALS).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committees of the University of New South Wales and South-Eastern Sydney and Illawarra Health Service gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
De-identified individual participant data collected during the Sydney Memory and Ageing Study are available to researchers who provide a methodologically sound proposal. Proposals should be directed to the Centre for Healthy Brain Ageing; to gain access, data requestors will need to sign a data access agreement.
